Pfizer IncChange company Symbol lookupSelect an option...PFE Pfizer IncHSTRF Hollister Biosciences IncT AT&T IncSPHD Invesco S&P 500® High Dividend Low Volatility ETFMSFT Microsoft CorpPEY Invesco High Yield Equity Dividend Achievers™ ETFBAC Bank of America CorpARI Apollo Commercial Real Estate Finance IncISNPY Intesa Sanpaolo SpABRKR Bruker CorpGo
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
|
|
|
|
| |
PFE's position in the Pharmaceuticals industry
| Industry Peers | MRK | LLY | BMY | RETA | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes... | Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through... Go to MRK summary | Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include... Go to LLY summary | Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products... Go to BMY summary | Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of... Go to RETA summary |
| 52-Week Change | VS. INDUSTRY | -8.56% | 45.98% | -3.45% | -45.18% |
| Market Cap | VS. INDUSTRY | $204.9B | $197.2B | $145.9B | $4.1B |
| Beta | VS. INDUSTRY | 0.4 | 0.4 | 0.6 | 1.5 |
| Dividend Yield | VS. INDUSTRY | 3.21% | 1.65% | 3.04% | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 17.81x | 33.75x | -- | -- |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $47.3B | $23.2B | $39.4B | $8.5M |
| Profit Margin | VS. INDUSTRY | 24.47% | 24.01% | -0.07% | -4,341.23% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -1.06% | 17.37% | 10.85% | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 3.00% | 6.28% | 62.97% | -73.69% |
| Data as of |
Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.